PRESS RELEASE published on 02/01/2024 at 12:30, 2 years 5 months ago Immunic to Participate in Investor and Scientific Conferences in February Immunic, Inc. (Nasdaq: IMUX) to participate in BioCapital Europe 2024 and ACTRIMS Forum 2024 in February and March, presenting clinical pipeline therapies and poster presentations Immunic, Inc. BioCapital Europe 2024 ACTRIMS Forum 2024 Clinical Pipeline Therapies Poster Presentations
PRESS RELEASE published on 11/02/2023 at 11:30, 2 years 8 months ago Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts
PRESS RELEASE published on 10/26/2023 at 12:30, 2 years 8 months ago Immunic to Participate in Scientific and Industry Conferences in November
PRESS RELEASE published on 10/16/2023 at 12:30, 2 years 8 months ago Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023
PRESS RELEASE published on 10/15/2023 at 12:30, 2 years 8 months ago Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023
PRESS RELEASE published on 10/11/2023 at 12:30, 2 years 9 months ago Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting
PRESS RELEASE published on 10/09/2023 at 22:01, 2 years 9 months ago Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
PRESS RELEASE published on 10/04/2023 at 12:30, 2 years 9 months ago Immunic to Participate in Scientific Conferences in October
PRESS RELEASE published on 09/06/2023 at 12:30, 2 years 10 months ago Immunic to Participate in Industry and Investor Conferences in September
PRESS RELEASE published on 08/17/2023 at 12:30, 2 years 10 months ago Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
Published on 07/14/2026 at 01:45, 4 hours 3 minutes ago Arctic Fox Lithium Approved for Trading on the OTCQB Venture Market and Announces DTC Eligibility
Published on 07/14/2026 at 00:01, 5 hours 47 minutes ago Captor Capital Announces Delay in its Annual Filings
Published on 07/13/2026 at 23:10, 6 hours 38 minutes ago Galaxy Ventures Inc. Announces Director Resignation
Published on 07/13/2026 at 21:35, 8 hours 13 minutes ago ATHA Energy Announces Corporate Activities Update
Published on 07/13/2026 at 20:00, 9 hours 48 minutes ago IBC Announces Share-Based Compensation to Directors
Published on 07/14/2026 at 04:45, 1 hour 3 minutes ago Asia’s Debut of LEAP East in HKCEC Marks Hong Kong’s Largest Inaugural Tech Summit
Published on 07/13/2026 at 22:30, 7 hours 18 minutes ago Half-year 2026 Results Media and Investor Conference Call and Webcast
Published on 07/13/2026 at 21:20, 8 hours 27 minutes ago Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Published on 07/13/2026 at 21:17, 8 hours 30 minutes ago EQS-Adhoc: Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Published on 07/13/2026 at 20:48, 9 hours ago EQS-Adhoc: Gateway Real Estate AG: Forecast for the financial year 2026
Published on 07/13/2026 at 18:00, 11 hours 48 minutes ago CP Icade - Icade reprend 100% de la propriété de la Tour Eqho à la Défense
Published on 07/13/2026 at 18:00, 11 hours 48 minutes ago PR Icade - Icade regains full ownership of the Eqho Tower in La Défense
Published on 07/13/2026 at 18:00, 11 hours 48 minutes ago THERMADOR GROUPE : publication du chiffre d'affaires semestriel 2026
